109 related articles for article (PubMed ID: 7791959)
1. Characterization of a serine peptidase responsible for the inactivation of endogenous cholecystokinin in human brain.
Rose C; Vargas F; Silhouette B; Devaux B; Schwartz JC
Neuropeptides; 1995 Mar; 28(3):157-60. PubMed ID: 7791959
[TBL] [Abstract][Full Text] [Related]
2. Protection by serine peptidase inhibitors of endogenous cholecystokinin released from brain slices.
Rose C; Camus A; Schwartz JC
Neuroscience; 1989; 29(3):583-94. PubMed ID: 2739903
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the role of "enkephalinase" in cholecystokinin inactivation.
Zuzel KA; Rose C; Schwartz JC
Neuroscience; 1985 May; 15(1):149-58. PubMed ID: 3892359
[TBL] [Abstract][Full Text] [Related]
4. Role of a serine endopeptidase in the hydrolysis of exogenous cholecystokinin by brain slices.
Camus A; Rose C; Schwartz JC
Neuroscience; 1989; 29(3):595-602. PubMed ID: 2662053
[TBL] [Abstract][Full Text] [Related]
5. A serine peptidase responsible for the inactivation of endogenous cholecystokinin in brain.
Rose C; Camus A; Schwartz JC
Proc Natl Acad Sci U S A; 1988 Nov; 85(21):8326-30. PubMed ID: 3186727
[TBL] [Abstract][Full Text] [Related]
6. Characterization and inhibition of a cholecystokinin-inactivating serine peptidase.
Rose C; Vargas F; Facchinetti P; Bourgeat P; Bambal RB; Bishop PB; Chan SM; Moore AN; Ganellin CR; Schwartz JC
Nature; 1996 Apr; 380(6573):403-9. PubMed ID: 8602240
[TBL] [Abstract][Full Text] [Related]
7. Characterization of aminopeptidases responsible for inactivating endogenous (Met5)enkephalin in brain slices using peptidase inhibitors and anti-aminopeptidase M antibodies.
Giros B; Gros C; Solhonne B; Schwartz JC
Mol Pharmacol; 1986 Mar; 29(3):281-7. PubMed ID: 2869404
[TBL] [Abstract][Full Text] [Related]
8. Immunolocalization of tripeptidyl peptidase II, a cholecystokinin-inactivating enzyme, in rat brain.
Facchinetti P; Rose C; Rostaing P; Triller A; Schwartz JC
Neuroscience; 1999; 88(4):1225-40. PubMed ID: 10336132
[TBL] [Abstract][Full Text] [Related]
9. Effects of thiorphan, bestatin and a novel metallopeptidase inhibitor JMV 390-1 on the recovery of neurotensin and neuromedin N released from mouse hypothalamus.
Kitabgi P; Dubuc I; Nouel D; Costentin J; Cuber JC; Fulcrand H; Doulut S; Rodriguez M; Martinez J
Neurosci Lett; 1992 Aug; 142(2):200-4. PubMed ID: 1454216
[TBL] [Abstract][Full Text] [Related]
10. Purification and characterization of tripeptidylpeptidase-II from post-mortem human brain.
Wilson C; Gibson AM; McDermott JR
Neurochem Res; 1993 Jul; 18(7):743-9. PubMed ID: 8396212
[TBL] [Abstract][Full Text] [Related]
11. A radioimmunoassay for the tripeptide Gly-Trp-Met, a major metabolite of endogenous cholecystokinin in brain.
Rose C; Vargas F; Bourgeat P; Schwartz JC
Neuropeptides; 1996 Jun; 30(3):231-5. PubMed ID: 8819147
[TBL] [Abstract][Full Text] [Related]
12. Peptidases involved in the inactivation of exogenous and endogenous enkephalins.
Schwartz JC; de la Baume S; Yi CC; Chaillet P; Marcais-Collado H; Costentin J
J Neural Transm Suppl; 1983; 18():235-43. PubMed ID: 6348211
[TBL] [Abstract][Full Text] [Related]
13. [Inhibition of the evoked liberation of (Met5)enkephalin from slices of globus pallidus in the presence of thiorphan and bestatin].
Giros B; de la Baume S; Gros C; Schwartz JC
C R Seances Acad Sci III; 1983; 297(13):609-12. PubMed ID: 6424884
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of tripeptidyl peptidase II. 2. Generation of the first novel lead inhibitor of cholecystokinin-8-inactivating peptidase: a strategy for the design of peptidase inhibitors.
Ganellin CR; Bishop PB; Bambal RB; Chan SM; Law JK; Marabout B; Luthra PM; Moore AN; Peschard O; Bourgeat P; Rose C; Vargas F; Schwartz JC
J Med Chem; 2000 Feb; 43(4):664-74. PubMed ID: 10691692
[TBL] [Abstract][Full Text] [Related]
15. Regional metabolism of Met-enkephalin and cholecystokinin on intact ratbrain slices: characterization of specific peptidases.
Konkoy CS; Davis TP
J Neurochem; 1995 Dec; 65(6):2773-82. PubMed ID: 7595577
[TBL] [Abstract][Full Text] [Related]
16. Role of delta opioid receptors in the effects of inhibitors of enkephalin-degrading peptidases on the horizontal and vertical components of locomotion in mice.
Michael-Titus A; Dourmap N; Costentin J; Schwartz JC
Neuropeptides; 1990 Feb; 15(2):89-100. PubMed ID: 1981928
[TBL] [Abstract][Full Text] [Related]
17. Lysosomal degradation of cholecystokinin-(29-33)-amide in mouse brain is dependent on tripeptidyl peptidase-I: implications for the degradation and storage of peptides in classical late-infantile neuronal ceroid lipofuscinosis.
Bernardini F; Warburton MJ
Biochem J; 2002 Sep; 366(Pt 2):521-9. PubMed ID: 12038963
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo effects of kelatorphan on enkephalin metabolism in rodent brain.
Waksman G; Bouboutou R; Devin J; Bourgoin S; Cesselin F; Hamon M; Fournie-Zaluski MC; Roques B
Eur J Pharmacol; 1985 Nov; 117(2):233-43. PubMed ID: 3865779
[TBL] [Abstract][Full Text] [Related]
19. Enkephalinase is involved in the degradation of endogenous substance P released from slices of rat substantia nigra.
Mauborgne A; Bourgoin S; Benoliel JJ; Hirsch M; Berthier JL; Hamon M; Cesselin F
J Pharmacol Exp Ther; 1987 Nov; 243(2):674-80. PubMed ID: 2445957
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of enkephalin metabolism by, and antinociceptive activity of, bestatin, an aminopeptidase inhibitor.
Chaillet P; Marçais-Collado H; Costentin J; Yi CC; De La Baume S; Schwartz JC
Eur J Pharmacol; 1983 Jan; 86(3-4):329-36. PubMed ID: 6572590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
